Organigram Invests Additional $2.5M in Hyasynth Biologicals
December 22, 2021
Organigram Holdings Inc. has invested an additional $2.5 million in secured convertible debentures of Hyasynth Biologicals Inc., bringing its total investment to $10.0 million. The financing is intended to advance Hyasynth's production scalability, R&D into rare cannabinoids and commercial partnerships as the company scales fermentation-based cannabinoid manufacturing.
- Buyers
- Organigram Holdings Inc.
- Targets
- Hyasynth Biologicals Inc.
- Industry
- Biotechnology
- Location
- Quebec, Canada
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
Synsus Private Label Partners Acquires Emerald Bioagriculture
March 23, 2026
Biotechnology
Synsus Private Label Partners, LLC (Synsus) announced it has acquired Emerald Bioagriculture (Emerald), a biostimulant technologies innovator. The deal is intended to expand Synsus’ technology portfolio and accelerate development and integration of eco-friendly, bio-based inputs for growers, turf managers, and homeowners.
-
Organigram Acquires Collective Project Limited to Enter U.S. Hemp-Derived THC Beverage Market
April 1, 2025
Food & Beverage
Organigram Global Inc. acquired 100% of Collective Project Limited for approximately C$6.2 million upfront, with milestone and earnout payments linked to future beverage revenue that could bring total contingent consideration to C$24 million. The deal gives Organigram an immediate footprint in the U.S. hemp-derived THC beverage market and accelerates its entry into the cannabis beverage category in Canada by adding Collective Project’s ready-to-drink hemp/cannabis beverage portfolio and existing U.S. retail listings.
-
Organigram Holdings Acquires Motif Labs Ltd.
December 6, 2024
Consumer Products
Organigram Holdings Inc. acquired 100% of Motif Labs Ltd. for $90 million upfront consideration (C$50M cash and C$40M in Organigram common shares) plus up to C$10M contingent share consideration. The acquisition gives Organigram #1 market share in the Canadian recreational cannabis market, adds Motif's extraction and high‑volume vape/IPR manufacturing capabilities and a Southwestern Ontario distribution hub, and is expected to deliver >C$10M of cost synergies over ~24 months.
-
Biosynth Acquires celares to Expand Bioconjugation and Polymer Drug Delivery Capabilities
July 11, 2023
Biotechnology
Biosynth, a Switzerland-based supplier of critical raw materials and manufacturing services, acquired Berlin-based celares, a developer and manufacturer of bioconjugates, activated PEGs and polymer-based drug delivery excipients. The acquisition strengthens Biosynth's capabilities in conjugate vaccines and bioconjugate drugs and adds GMP bioconjugation and PEGylation manufacturing in Berlin to its service offering.
-
Organigram Holdings Inc. Acquires Laurentian Organic Inc.
December 21, 2021
Consumer Products
Organigram Holdings Inc. acquired all of the issued and outstanding shares of Laurentian Organic Inc. in a cash-and-share transaction with aggregate upfront consideration of CAD 36 million plus potential earnouts. The acquisition brings the Tremblant Cannabis and Laurentian craft brands into Organigram’s portfolio, strengthens its presence in Quebec, and expands its premium/hash product offering to accelerate revenue and EBITDA growth.
-
Cyrus Biotechnology Acquires Orthogonal Biologics and Raises $18M Series B
December 6, 2021
Biotechnology
Cyrus Biotechnology completed an acquisition of Orthogonal Biologics and closed an $18 million Series B financing to build an integrated software-and-screening pre-clinical biologics discovery firm. The financing was led by a syndicate including OrbiMed Advisors, Trinity Ventures, Agent Capital and other investors, with Selecta Bioscience joining as a strategic investor; the acquisition brings Orthogonal’s deep mutational scanning protein engineering capabilities into Cyrus’s computational discovery platform.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.